REGENXBIO Q4 net loss $59.9M ($1.38/share); revenue $31.3M vs $398.7M YoY; cash $565M

REGENXBIO Inc.

2022-FY EPS reported -$6.50 revenue$112,724,000

Full-year 2022 net loss $280.3M ($6.50/share) vs net income $127.8M in 2021.
Revenue fell to $112.7M in 2022 from $470.3M, driven by $370M non-recurring AbbVie collaboration revenue in 2021.
Zolgensma royalties rose to $101.9M in 2022 from $95.0M in 2021.
Cash, equivalents and marketable securities $565.2M as of Dec 31, 2022, down from $849.3M; runway into 2025.
RGX-314 pivotal trials ongoing with BLA expected in 2024; RGX-121 pivotal enrollment to complete H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENXBIO Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 28, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.